DELHI, INDIA, November 22, 2022 /EINPresswire.com/ -- IMARC Group’s latest report, titled “India Idiopathic Pulmonary Fibrosis Treatment Market Research Report: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, the India idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 9.10% during 2022-2027.
Idiopathic pulmonary fibrosis (IPF) is an acute lung disease distinguished by a progressive and irreversible reduction in lung functioning characterized by the thickening and damaging of air sac walls. This disease is characterized by the development of scar tissue within the lungs that begins at the edges and progresses toward the center, thus causing difficulties in breathing and insufficient delivery of oxygen to the body parts. Its symptoms include fatigue, nail clubbing, dry cough, weight loss, joint pain, and shortness of breath. It is diagnosed through lung biopsies, chest imaging studies, pulmonary function and antibody tests and can be treated using antifibrotic drugs, such as pirfenidone and nintedanib, and various other methods, including oxygen therapy, pulmonary rehabilitation, symptom management, and lung transplant.
Request Free Sample Report (Exclusive Offer on this report): www.imarcgroup.com/india-idiopathic-pulmonary-fibrosis-treatment-market/requestsample
India Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The increasing prevalence of idiopathic pulmonary fibrotic diseases among the masses is driving the market in India. This can be attributed to the increasing consumption of nicotine products, such as cigarettes. Moreover, the escalating demand for cost-effective drugs and the introduction of advanced treatment options for the treatment of IPF are contributing to the market. Furthermore, continual technological advancements in the healthcare sector that aid in diagnosis and screening are creating a positive market outlook. The market is further driven by other factors, such as the growing awareness regarding IPF treatments among individuals, the rising geriatric population, continual improvements in the healthcare infrastructure, and extensive research and developments (R&D) activities conducted by key players to manufacture and discover novel medicines and treatments.
Ask Analyst for Instant Discount and Download Full Report with TOC & List of Figure: www.imarcgroup.com/india-idiopathic-pulmonary-fibrosis-treatment-market
Key Market Segmentation:
Breakup by Drug Class:
• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors
Breakup by End User:
• Long-term Care Facilities
Breakup by Region:
• North India
• West and Central India
• South India
• East India
Competitive Landscape with Key Players:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Key Highlights of the Report:
• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Browse More Research Reports:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited
email us here